PharmaCyte Biotech Reverse Stock Split
PharmaCyte Biotech implemented a 1-for-19 reverse stock split of its common stock effective November 12, 2026. The split consolidated approximately 10.8 million outstanding shares into roughly 0.57 million shares to increase the per-share trading price. The action is intended to help the company regain compliance with the Nasdaq minimum bid price requirement for continued listing.